ty -jour t1-在现代管理心力衰竭时代的急性肺动脉高压发作后五年生存，欧洲呼吸杂志jo -eur Respir j do -10.1183/13993003.00466-2021 sp -2100466 au -savale-，Laurent Au -Vuillard，Constance au -Pichon，JérémieAu -boucly，AthénaïsAu -Roche -Roche，Anne Au -Jevnikar，Mitja au -Ebstein，Nathan Au -Ja au-Mercier，Olaf au- sitbon，Olivier au -Fadel，Elie au -Humbert，Marc Y1-2021/01/01 UR -http：//www.qdcxjkg.com/content.com/content/content/early/early/2021/05/05/28/28/1399993003.003003.003003.003003.003003.003003.003003.003003.003003.004666-2021.ABSTRACT N2-急性代偿性肺动脉高压（PAH）的特征是右心衰竭（RHF）的临床迹象迅速恶化，随后的充血和全身性循环不足可能导致多系统器官衰竭[1-3]。急性代偿性RHF的短期结局非常差，并且仍然是PAH死亡率的第一个原因[4，5]。急性代偿PAH的重症监护是基于触发因素的治疗，仔细的液体管理以及改善心脏功能并减少右心室后负荷的策略[1]。但是，这种医疗策略并不总是足以恢复对右心室的后载之间的持久平衡与赔偿能力之间的持久平衡。如果尽管有最大的医疗治疗，但现在应在选定的候选者中考虑使用机械支撑进行肺移植，或者不太常见地将机械支撑使用作为可治疗的右侧心力衰竭病因的患者恢复的桥梁[1]。静脉静脉外膜氧合（ECMO）目前是支持PAH患者右心室的最广泛使用的策略。该策略，结合器官分配规则的变化，以优先考虑短期威胁生命状况的患者，这将有助于提高终点PAH的合格患者的生存[6]。然而，在现代的机械支持和高优先肺移植的现代管理时代，尚未对ICU接受严重急性RHF管理的患者长期生存。Footnotesthis手稿最近在欧洲呼吸道杂志上被接受。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Savale reports personal fees from Actelion, personal fees from Bayer, grants and personal fees from GSK, outside the submitted work; .Conflict of interest: Dr. Vuillard has nothing to disclose.Conflict of interest: Dr. Pichon has nothing to disclose.Conflict of interest: Dr. Boucly has nothing to disclose.Conflict of interest: Dr. Roche has nothing to disclose.Conflict of interest: Dr. Jevnikar has nothing to disclose.Conflict of interest: Dr. Ebstein has nothing to disclose.Conflict of interest: Dr. Jais has nothing to disclose.Conflict of interest: Dr. Le Pavec has nothing to disclose.Conflict of interest: Pr. MONTANI reports grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK, personal fees from Pfizer, grants, personal fees and non-financial support from MSD, personal fees from Chiesi, personal fees from Boerhinger, non-financial support from Acceleron, personal fees from Incyte Biosciences France, outside the submitted work.Conflict of interest: Dr. Mercier has nothing to disclose.Conflict of interest: Dr. SITBON reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, grants and personal fees from Bayer HealthCare, grants and non-financial support from Merck, grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from Arena Pharmaceuticals, outside the submitted work; .Conflict of interest: Dr. Fadel has nothing to disclose.Conflict of interest: Dr. Humbert reports personal fees from Acceleron, grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK, personal fees from Merck, personal fees from Novartis, personal fees from Astrazeneca, personal fees from Sanofi, outside the submitted work. ER -